Optiscan Imaging (ASX:OIL) said it has completed the first prototype to collect images from the gastrointestinal tract (GI) and has started a pre-clinical study with the University Medical Centre of the Johannes Gutenberg University Mainz, Germany, in a Monday filing with the Australian bourse.
The study is aimed at capturing images of the GI tract to diagnose and treat related diseases such as colon cancer, the filing said.